Neurocrine Biosciences | 销售和管理费用

Selling And Administration Expenses 更改 日
AbbVie USD 3.32B 291M 2024-03
Acadia Pharmaceuticals USD 107.99M 3.47M 2024-03
Agios Pharmaceuticals USD 31.01M 4.29M 2024-03
ALKERMES USD 179.75M 9.96M 2024-03
Alnylam Pharmaceuticals USD 210.8M 12.67M 2024-03
Amgen USD 1.81B 44M 2024-03
Biogen USD 581.5M 27M 2024-03
BioMarin Pharmaceutical USD 225.91M 49.12M 2024-03
Cytokinetics USD 45.5M 1.39M 2024-03
Dynavax Technologies USD 44.06M 4.27M 2024-03
Exelixis USD 113.98M 24.16M 2024-03
Gilead Sciences USD 1.38B 233M 2024-03
Halozyme Therapeutics USD 35.13M 2.47M 2024-03
Incyte USD 300.3M 6.44M 2024-03
Intra Cellular Therapies USD 113.08M 8.36M 2024-03
Ionis Pharmaceuticals USD 52.64M 18.37M 2024-03
Neurocrine Biosciences USD 243.1M 38.9M 2024-03
Pfizer USD 3.5B 976M 2024-03
Prothena USD 17.46M 524K 2024-03
Regeneron Pharmaceuticals USD 689M 48.7M 2024-03
Repligen USD 60.99M 3.47M 2024-03
Sarepta Therapeutics USD 127M 6.11M 2024-03
Teva Pharmaceutical Industries USD 886M 15M 2024-03
Ultragenyx Pharmaceutical USD 78.16M 1.33M 2024-03
Vertex Pharmaceuticals USD 342.7M 78.9M 2024-03



Neurocrine Biosciences 销售和管理费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Jun 2024.